Literature DB >> 9678703

The fragile X syndrome.

B B de Vries1, D J Halley, B A Oostra, M F Niermeijer.   

Abstract

The fragile X syndrome is characterised by mental retardation, behavioural features, and physical features, such as a long face with large protruding ears and macro-orchidism. In 1991, after identification of the fragile X mental retardation (FMR1) gene, the cytogenetic marker (a fragile site at Xq27.3) became replaced by molecular diagnosis. The fragile X syndrome was one of the first examples of a "novel" class of disorders caused by a trinucleotide repeat expansion. In the normal population, the CGG repeat varies from six to 54 units. Affected subjects have expanded CGG repeats (>200) in the first exon of the FMR1 gene (the full mutation). Phenotypically normal carriers of the fragile X syndrome have a repeat in the 43 to 200 range (the premutation). The cloning of the FMR1 gene led to the characterisation of its protein product FMRP, encouraged further clinical studies, and opened up the possibility of more accurate family studies and fragile X screening programmes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9678703      PMCID: PMC1051369          DOI: 10.1136/jmg.35.7.579

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  166 in total

1.  Applicability of a checklist for clinical screening of the fragile X syndrome.

Authors:  M Arvio; M Peippo; K O Simola
Journal:  Clin Genet       Date:  1997-10       Impact factor: 4.438

2.  The fragile X mental retardation protein is associated with ribosomes.

Authors:  E W Khandjian; F Corbin; S Woerly; F Rousseau
Journal:  Nat Genet       Date:  1996-01       Impact factor: 38.330

3.  Nucleus basalis magnocellularis and hippocampus are the major sites of FMR-1 expression in the human fetal brain.

Authors:  M Abitbol; C Menini; A L Delezoide; T Rhyner; M Vekemans; J Mallet
Journal:  Nat Genet       Date:  1993-06       Impact factor: 38.330

4.  Population screening for fragile-X syndrome.

Authors:  P N Howard-Peebles; A Maddalena; S H Black; J D Schulman
Journal:  Lancet       Date:  1993-03-20       Impact factor: 79.321

5.  Association of FMRP with ribosomal precursor particles in the nucleolus.

Authors:  R Willemsen; C Bontekoe; F Tamanini; H Galjaard; A Hoogeveen; B Oostra
Journal:  Biochem Biophys Res Commun       Date:  1996-08-05       Impact factor: 3.575

6.  Origin of the supernumerary X chromosome in a patient with fragile X and Klinefelter syndrome.

Authors:  K G Kupke; A L Soreng; U Müller
Journal:  Am J Med Genet       Date:  1991 Feb-Mar

7.  Population studies of the fragile X: a molecular approach.

Authors:  P A Jacobs; H Bullman; J Macpherson; S Youings; V Rooney; A Watson; N R Dennis
Journal:  J Med Genet       Date:  1993-06       Impact factor: 6.318

8.  FMR1 protein: conserved RNP family domains and selective RNA binding.

Authors:  C T Ashley; K D Wilkinson; D Reines; S T Warren
Journal:  Science       Date:  1993-10-22       Impact factor: 47.728

9.  Population screening for fragile X.

Authors:  G Turner; H Robinson; S Laing; M van den Berk; A Colley; A Goddard; S Sherman; M Partington
Journal:  Lancet       Date:  1992-05-16       Impact factor: 79.321

10.  Rapid antibody test for fragile X syndrome.

Authors:  R Willemsen; S Mohkamsing; B de Vries; D Devys; A van den Ouweland; J L Mandel; H Galjaard; B Oostra
Journal:  Lancet       Date:  1995-05-06       Impact factor: 79.321

View more
  21 in total

1.  Genetics 101: polymerase chain reaction.

Authors:  Alison Sinclair
Journal:  CMAJ       Date:  2002-10-29       Impact factor: 8.262

Review 2.  Fragile X syndrome: the GABAergic system and circuit dysfunction.

Authors:  Scott M Paluszkiewicz; Brandon S Martin; Molly M Huntsman
Journal:  Dev Neurosci       Date:  2011-09-21       Impact factor: 2.984

3.  Poly(ADP-ribose) glycohydrolase is a component of the FMRP-associated messenger ribonucleoparticles.

Authors:  Jean-Philippe Gagné; Marie-Eve Bonicalzi; Pierre Gagné; Marie-Eve Ouellet; Michael J Hendzel; Guy G Poirier
Journal:  Biochem J       Date:  2005-12-15       Impact factor: 3.857

Review 4.  Specific genetic disorders and autism: clinical contribution towards their identification.

Authors:  David Cohen; Nadège Pichard; Sylvie Tordjman; Clarisse Baumann; Lydie Burglen; Elsa Excoffier; Gabriela Lazar; Philippe Mazet; Clément Pinquier; Alain Verloes; Delphine Héron
Journal:  J Autism Dev Disord       Date:  2005-02

5.  Abnormal development of dendritic spines in FMR1 knock-out mice.

Authors:  E A Nimchinsky; A M Oberlander; K Svoboda
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

6.  Screening for the fragile X syndrome among the mentally retarded: a clinical study. The Collaborative Fragile X Study Group.

Authors:  B B de Vries; S Mohkamsing; A M van den Ouweland; E Mol; K Gelsema; M van Rijn; A Tibben; D J Halley; H J Duivenvoorden; B A Oostra; M F Niermeijer
Journal:  J Med Genet       Date:  1999-06       Impact factor: 6.318

7.  Evaluation of CAG repeat length of androgen receptor expressing cells in human testes showing different pictures of spermatogenic impairment.

Authors:  Daniela Fietz; Joachim Geyer; Sabine Kliesch; Jörg Gromoll; Martin Bergmann
Journal:  Histochem Cell Biol       Date:  2011-10-25       Impact factor: 4.304

8.  Genetic Counseling for Fragile X Syndrome: Recommendations of the National Society of Genetic Counselors.

Authors:  N McIntosh; L W Gane; A McConkie-Rosell; R L Bennett
Journal:  J Genet Couns       Date:  2000-08       Impact factor: 2.537

9.  The fragile X mental retardation protein inhibits translation via interacting with mRNA.

Authors:  Z Li; Y Zhang; L Ku; K D Wilkinson; S T Warren; Y Feng
Journal:  Nucleic Acids Res       Date:  2001-06-01       Impact factor: 16.971

10.  Targeting the endocannabinoid system in the treatment of fragile X syndrome.

Authors:  Arnau Busquets-Garcia; Maria Gomis-González; Thomas Guegan; Carmen Agustín-Pavón; Antoni Pastor; Susana Mato; Alberto Pérez-Samartín; Carlos Matute; Rafael de la Torre; Mara Dierssen; Rafael Maldonado; Andrés Ozaita
Journal:  Nat Med       Date:  2013-03-31       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.